(Alliance News) – Oxford Nanopore Technologies PLC said on Wednesday it is collaborating with UK Biobank on an “epigenetic dataset targeting the causes of cancer, dementia and complex diseases”.
UK Biobank is a biomedical database and research resource.
The Oxford-based DNA and RNA sequencing specialist said the partnership “will analyze the epigenome using 50,000 participant samples”. Epigenetics is the study of how lifestyle choices can change DNA.
Oxford Nanopore does not expect the partnership to change its financial guidance for 2024 and the medium term, but noted that the additional revenues will support its previously stated revenue target of over 30% growth in constant currency, on a compound annual growth rate between 2024 and 2027.
“This project represents a significant advance in epigenetics research, an increasingly important area of study linked to the causes of disease, their progression and response to treatments. The collaboration with UK Biobank to create the largest set of epigenetic data in the world is part of our commitment to driving discovery in healthcare and genomics,” said Gordon Sanghera, Chief Executive Officer. “By collecting comprehensive methylation data, we want to open new doors to understanding diseases, particularly cancer and dementia, and ultimately enable more personalized and effective treatments for patients.”
According to Tuesday’s FTSE Russell, Oxford Nanopore is expected to be promoted to the FTSE 250.
Clean energy technology developer Ceres Power Holdings PLC, bank, broker and asset manager Close Brothers Group PLC, Carex owner PZ Cussons PLC and oilfield and engineering services provider John Wood Group PLC are about to leave the FTSE 250.
Meal delivery company Deliveroo PLC, U.S. natural gas producer Diversified Energy Co PLC, transportation operator Mobico Group PLC and Oxford Nanopore are expected to replace them.
The Oxford-based DNA and RNA sequencing specialist saw its shares rise 3.5%.
Shares in Oxford Nanopore rose 3.2% to 140.41 pence each on Wednesday morning in London.
By Tom Budszus, Alliance News Editor
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All rights reserved.
